AstraZeneca’s (AZN) “Overweight” Rating Reiterated at JPMorgan Chase & Co.

JPMorgan Chase & Co. reaffirmed their overweight rating on shares of AstraZeneca (LON:AZN) in a research note issued to investors on Monday, Marketbeat.com reports.

Other research analysts also recently issued research reports about the company. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a £110 price objective on shares of AstraZeneca in a report on Wednesday, July 30th. Shore Capital reaffirmed a “buy” rating and set a £145 price objective on shares of AstraZeneca in a report on Tuesday, October 7th. Finally, Berenberg Bank reaffirmed a “buy” rating and set a £142 price objective on shares of AstraZeneca in a report on Monday, September 1st. Three research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of £134.25.

AstraZeneca Stock Down 0.7%

Shares of AZN opened at £126.44 on Monday. The company has a market capitalization of £196.01 billion, a P/E ratio of 2,381.17, a PEG ratio of 0.86 and a beta of 0.17. The company has a debt-to-equity ratio of 73.83, a current ratio of 0.93 and a quick ratio of 0.59. AstraZeneca has a one year low of GBX 9,573.51 and a one year high of £129.72. The business’s 50 day simple moving average is £118.42 and its 200-day simple moving average is £109.75.

Insider Activity at AstraZeneca

In other AstraZeneca news, insider Aradhana Sarin sold 9,563 shares of the company’s stock in a transaction on Thursday, August 14th. The shares were sold at an average price of £115.12, for a total transaction of £1,100,892.56. Insiders own 0.14% of the company’s stock.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.